ContraFect Corporation Announces Third Quarter 2014 Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ContraFect Corporation Announces Third Quarter 2014 Results

YONKERS, NY--(Marketwired - Nov 14, 2014) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced results for the third quarter ended September 30, 2014. The Company closed its initial public offering (IPO) on August 1, 2014. For the three month period ended September 30, 2014, the Company posted a net loss of $16.4 million. Cash and cash equivalents totaled $31.3 million at the end of the quarter.

"Throughout the quarter we have continued our mission to address treatments for life-threatening, drug-resistant infections; one of the healthcare community's major unmet needs," said Julia P. Gregory, chief executive officer of ContraFect. "We have continued to advance the development of our lead program, CF-301, which is a potential first-in-class molecule to address serious, life-threatening infections in the hospital, including those caused by the drug-resistant MRSA superbug. We plan to resubmit our IND for CF-301 by the end of the year. Our CF-404 program, which is a universal treatment for life-threatening influenza, has also made great strides and we are currently preparing to conduct IND enabling studies with that compound."

Key Highlights:

  • In August 2014, ContraFect completed a successful initial public offering, raising $41.3 million. The Company's common stock is trading under the symbol "CFRX" and the two publicly traded warrants originally part of the unit offering are traded under the symbols "CFRXW" and "CFRXZ."

  • ContraFect was invited to give an oral presentation of our data on CF-301 on September 9, 2014 at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The presentation, titled, "Efficacy of Single-Dose Lysin CF-301 in Combination with Vancomycin (VAN) or Daptomycin (DAP) in Experimental Endocarditis (IE) Due to Methicillin-Resistant Staphylococcus aureus (MRSA)," was presented by Michael Wittekind, Ph.D., chief scientific officer of ContraFect. The data supported ContraFect's new alternative approach to treating Staph bacteremia, demonstrating the powerful combination of CF-301 and standard-of-care antibiotics in a well-established model of infectious endocarditis.

  • In September 2014, ContraFect announced that CF-404, its universal influenza treatment, received a $3.3 million, 3.5 year Advanced Technology Fast Track Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) to fund its pre-clinical development.

  • Shortly after the end of the quarter, ContraFect entered into a collaborative research agreement with the National Institute for Viral Disease Control and Prevention, China CDC ("IVDC") to advance research and development of CF-404, its universal influenza treatment.

Financial Results:

Operating expenses for the quarter ended September 30, 2014 were $4.6 million, with $2.4 million attributable to research and development. This compares to operating expenses of $3.6 million and research and development expenses of $2.1 million for the same period in 2013. The Company incurred a net loss for the quarter ended September 30, 2014 of $16.4 million compared to a net loss of $4.4 million in the prior year period.

For the nine month period ended September 30, 2014, operating expenses were $12.1 million, with $6.5 million attributable to research and development. This compares to operating expenses of $11.9 million and research and development expenses of $6.6 million for the same period in 2013. The Company incurred a net loss for the nine months ended September 30, 2014 of $25.4 million compared to a net loss of $12.7 million in the prior year period.

The conversion of all of the Company's notes into common stock on the closing of the IPO resulted in substantially all of the $11.8 million non-cash total other expenses in the quarter which increased our net loss for both the three and nine month periods ended September 30, 2014. Our operating expenses and continued investment in research and development demonstrate how we are deploying our resources. These non-recurring, non-cash charges are not indicative of future costs.

We expect that we will conclude the year with cash of approximately $23-$25 million and full year operating expenses of approximately $18-$19 million.

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.

FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar references to future periods. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Specific forward-looking statements in this release include statements regarding our expected timetable for submitting our IND for CF-301, our expectations regarding our full year operating expenses and expected cash balance at the end of the year. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

(Tables to Follow)

   
CONTRAFECT CORPORATION  
Condensed Balance Sheets  
   
    September 30,
2014
  December 31,
2013
 
    (unaudited)   (audited)  
Assets              
Current assets:              
  Cash and cash equivalents   $ 31,320,237   $ 4,145,270  
  Prepaid expenses and other current assets     417,143     198,410  
Total current assets     31,737,380     4,343,680  
Long-term assets     2,464,105     5,340,155  
Total assets   $ 34,201,485   $ 9,683,835  
Liabilities and stockholders' deficit              
Current liabilities   $ 4,228,863   $ 7,116,846  
Convertible notes payable and other long-term liabilities     403,696     15,585,162  
Total liabilities     4,692,559     22,702,008  
               
Total stockholders' equity (deficit)     29,508,926     (52,910,500 )
Total liabilities, convertible preferred stock, and stockholders' equity (deficit)   $ 34,201,485   $ 9,683,835  
               
               
               
CONTRAFECT CORPORATION  
Unaudited Statements of Operations  
   
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2014     2013     2014     2013  
Operating expenses:                                
  Research and development   $ 2,363,957     $ 2,108,397     $ 6,545,496     $ 6,601,105  
  General and administrative     2,274,569       1,465,708       5,561,432       5,249,485  
Total operating expenses     4,638,526       3,574,105       12,106,928       11,859,590  
Loss from operations     (4,638,526 )     (3,574,105 )     (12,106,928 )     (11,859,590 )
Other income (expense)                                
  Interest expense, net     (11,067,209 )     (784,075 )     (12,414,240 )     (838,776 )
  Refundable state tax credits     --       --       424,649       --  
  Change in fair value of warrant and embedded derivative liabilities     (691,943 )     --       (1,315,894 )     --  
Total other income (expense)     (11,759,152 )     (784,075 )     (13,305,485 )     (838,776 )
  Net loss     (16,397,678 )     (4,358,180 )     (25,412,413 )     (12,689,366 )
Preferred stock dividend in-kind     --       --       (4,468,452 )     --  
  Net loss attributable to common stockholders   $ (16,397,678 )   $ (4,358,180 )   $ (29,880,865 )   $ (12,689,366 )
Per share information:                                
  Net loss per share of common stock, basic and diluted*   $ (1.22 )   $ (4.31 )   $ (5.76 )   $ (12.54 )
  Basic and diluted weighted average shares outstanding*     13,403,595       1,011,997       5,187,920       1,011,670  
                                 
  *Basic and diluted net loss per share attributable to common stockholders and weighted average shares outstanding were impacted by the conversion of all the Company's outstanding convertible preferred stock and convertible notes payable on the closing of the Company's initial public offering on August 1, 2014.
   

Contact:

Barry Kappel, Ph.D., MBA
SVP Business Development
Tel: 914-207-2300
E-Mail: Email Contact
or visit: www.contrafect.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 150

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 176

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 161

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 191

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 154

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 261

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Updates for KinderCare Learning Investors Ahead of Deadline

Updated Category News Views 178

Urgent Notice for KinderCare Learning Companies, Inc. Investors Investors of KinderCare Learning Companies, Inc. (NYSE: KLC) should be aware of an essential deadline approaching shortly. Rosen Law Firm, a prominent name in investor rights law, is urging shareholders to take action as we approach an important date in the ongoing securities class action lawsuit. Why This...

Continue Reading
Exploring Current Trading Trends and Insights on Sea Ltd

Updated Category News Views 320

Understanding the Options Trading Activity for Sea Ltd In recent times, there has been notable bullish positioning by investors concerning Sea Ltd (NYSE: SE). Retail traders should certainly pay attention to these movements. Significant trading activity often indicates that investors may possess undisclosed insights or information related to the company's performance....

Continue Reading
Cornish Metals Expands Share Capital with New Stock Options

Updated Category News Views 214

Cornish Metals Strengthens Its Financial Position Vancouver-based Cornish Metals Inc. (TSX-V: CUSN, LSE: CUSN) is excited to announce a significant move to bolster its financial stature. The company, known for its focus on mineral exploration and development, specifically its permitted South Crofty tin project, has exercised stock options resulting in the issuance of...

Continue Reading
PRA Group Outlines Investor Conferences for Late 2024

Updated Category News Views 94

PRA Group to Showcase at Upcoming Investor Conferences PRA Group, Inc. (Nasdaq: PRAA), known for its expertise in acquiring and collecting nonperforming loans, has announced its lineup for several significant investor conferences in the coming months. This is an exciting opportunity for attendees to gain insights into the company's strategies and performance. Details on...

Continue Reading
Latino Parents Face Financial Strain, Seek AI Help

Updated Category News Views 103

Feeling the Heat: Latino Parents in U.S. Grappling With Rising Costs If you've ever wondered how families can keep floating in this economic sea, take a look at the Latino community in the U.S., particularly those with children. The latest BMO Real Financial Progress Index unpacks a story of strain, adaptation, and a surprising technology push. Parental Challenges: The...

Continue Reading